References
- Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21
- National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. 2009. Available at: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf [Last accessed 19 July 2013]
- Owen V, Seetho I, Idris I. Predictors of responders to insulin therapy in type 2 diabetes among adults with type 2 diabetes. Diabetes Obes Metabol 2010;12:865-70
- Polonsky KS, Given BD, Van Cauter E. Twenty-four hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Investig 1988;81:442-8
- Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous infusion versus multiple daily injection in older adults with type 2 diabetes. Diabetes Care 2005;28:1568-73
- Schwartz S, Zagar AJ, Althouse SK, et al. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Therapeut 2006;28:1649-57
- Tanaka M, Ishii H. Pre-mixed rapid-acting insulin 50/50 analogue twice daily is useful not only for controlling post-prandial blood glucose, but also for stabilizing the diurnal variation of blood glucose levels: switching from pre-mixed insulin 70/30 or 75/25 to pre-mixed insulin 50/50. J Int Med Res 2010;38:674-80
- Shimizu H, Monden T, Matsumura M, et al. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients. Yonsei Med J 2010;51:845-9
- Schernthaner G, Kopp HP, Ristic S, et al. Metabolic control in patients with type 2 diabetes using Humalog® Mix50™ injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004;36:188-93
- Mamza J, Mehta R, Idris I. Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study. Open diabetes research and care. BMJ 2014;2:e000021
- Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52
- Masuda H, Sakamoto M, Irie J, et al. Comparison of twice daily injections of biphasic insulin lispro and basal bolus therapy: glycaemic control and quality of life of insulin-naïve type 2 diabetic patients. Diabetes Obes Metabol 2008;10:1261-5
- Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycaemic control in insulin-using adults with type 2 diabetes. Diabetes Care 2000;23:272-7
- Thong KY, Jose B, Blann AD, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011;93:e87-91